Evidence map›Paper›PMID 41706716›Full record

ArticlePloS one2026

Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study.

Yael Eshet, Liran Domachevsky, Noam Tau, Gregory Peters Founshtein, Michal Eifer, Jair Bar, Iris Eshed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yael EshetDepartment of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.ORCID https://orcid.org/0000-0002-8339-5823
Liran DomachevskyDepartment of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.
Noam TauDepartment of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
Gregory Peters FounshteinDepartment of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.
Michal EiferDepartment of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.
Jair BarInstitute of Oncology, Sheba Medical Center, Ramat Gan, Israel.
Iris EshedDepartment of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesProgressive arthropathy was anecdotally described in patients exposed to crizotinib, a receptor tyrosine kinases inhibitor (TKI) used to treat anaplastic lymphoma kinase (ALK) or ROS Proto-Oncogene 1 (ROS1) positive non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence of this adverse effect.

methodsWe retrospectively evaluated imaging studies of all patients in our institution receiving TKI for ALK-rearranged or ROS1-positive NSCLC (crizotinib, alectinib, lorlatinib, brigatinib).

resultsBetween February 2012 and August 2023, out of a total number of 71 subjects (51% male, 36-88 years old) who received TKI's for ALK-rearranged/ ROS1 positive NSCLC, 34/71 (47%) were exposed at least once to crizotinib treatment, while the other 37/71 (53%) patients received other TKI's. Significantly higher incidence (p = 0.02) of irreversible, progressive arthropathy in one or more joints was detected in 18% (6/34, 95% CI: 0.1-0.26) of crizotinib-treated patients, up to 6 years after treatment initiation. Imaging findings included synovial proliferation and progressive arthropathy in hip and shoulder joints, and vertebral endplate destruction.

conclusionWe found progressive arthropathy, mostly painless, in one or more joints or intervertebral spaces of patients receiving crizotinib for NSCLC.

Indexed as

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungCrizotinibLung NeoplasmsProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsAdultAgedAged, 80 and overAminopyridinesFemaleGene RearrangementHumansLactamsMaleALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseCrizotinibLactamslorlatinibMAS1 protein, humanPiperidinesProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsPyrazolesROS1 protein, human

Identifiers

PMID41706716
PMCPMC12915974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.